Cargando…
SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China
Objectives: To explore and understand the SARS-CoV-2 seroprevalence of convalescents, the association between antibody levels and demographic factors, and the seroepidemiology of convalescents of COVID-19 till March 2021. Methods: We recruited 517 voluntary COVID-19 convalescents in Sichuan Province...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577692/ https://www.ncbi.nlm.nih.gov/pubmed/34765580 http://dx.doi.org/10.3389/fpubh.2021.716483 |
_version_ | 1784596111889006592 |
---|---|
author | Zhou, Lijun Li, Cheng Yang, Huiping Yuan, Heng Pan, Ming Cheng, Xiuwei Xiao, Chongkun Su, Xiaoyan Zhu, Yuanfang Xu, Jianan Tang, Jianxiang Du, Xunbo Peng, Huanwen Chen, Xiao Huang, Tao Liao, Hongxiu Xian, Deqiang Wang, HaoZhou Liu, Wenwu Zhou, Ping Zhang, Zhengdong Liu, Juan Wu, Xianping Zhang, Tao |
author_facet | Zhou, Lijun Li, Cheng Yang, Huiping Yuan, Heng Pan, Ming Cheng, Xiuwei Xiao, Chongkun Su, Xiaoyan Zhu, Yuanfang Xu, Jianan Tang, Jianxiang Du, Xunbo Peng, Huanwen Chen, Xiao Huang, Tao Liao, Hongxiu Xian, Deqiang Wang, HaoZhou Liu, Wenwu Zhou, Ping Zhang, Zhengdong Liu, Juan Wu, Xianping Zhang, Tao |
author_sort | Zhou, Lijun |
collection | PubMed |
description | Objectives: To explore and understand the SARS-CoV-2 seroprevalence of convalescents, the association between antibody levels and demographic factors, and the seroepidemiology of convalescents of COVID-19 till March 2021. Methods: We recruited 517 voluntary COVID-19 convalescents in Sichuan Province and collected 1,707 serum samples till March 2021. Then we reported the seroprevalence and analyzed the associated factors. Results: Recent travel history was associated with IgM levels. Convalescents who had recent travel history were less likely to be IgM antibody negative [OR = 0.232, 95% CI: (0.128, 0.420)]. Asymptomatic cases had, approximately, twice the odds of being IgM antibody negative compared with symptomatic cases [OR = 2.583, 95% CI: (1.554, 4.293)]. Participants without symptoms were less likely to be IgG seronegative than those with symptoms [OR = 0.511, 95% CI: (0.293, 0.891)]. Convalescents aged 40–59 were less likely to be IgG seronegative than those aged below 20 [OR = 0.364, 95% CI: (0.138, 0.959)]. The duration of positive IgM antibodies persisted 365 days while the IgG persisted more than 399 days. Conclusions: Our findings suggested that recent travel history might be associated with the antibody levels of IgM, while age could be associated with the antibody levels of IgG. Infection type could be associated with both antibody levels of IgM and IgG that declined quicker in asymptomatic cases. |
format | Online Article Text |
id | pubmed-8577692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85776922021-11-10 SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China Zhou, Lijun Li, Cheng Yang, Huiping Yuan, Heng Pan, Ming Cheng, Xiuwei Xiao, Chongkun Su, Xiaoyan Zhu, Yuanfang Xu, Jianan Tang, Jianxiang Du, Xunbo Peng, Huanwen Chen, Xiao Huang, Tao Liao, Hongxiu Xian, Deqiang Wang, HaoZhou Liu, Wenwu Zhou, Ping Zhang, Zhengdong Liu, Juan Wu, Xianping Zhang, Tao Front Public Health Public Health Objectives: To explore and understand the SARS-CoV-2 seroprevalence of convalescents, the association between antibody levels and demographic factors, and the seroepidemiology of convalescents of COVID-19 till March 2021. Methods: We recruited 517 voluntary COVID-19 convalescents in Sichuan Province and collected 1,707 serum samples till March 2021. Then we reported the seroprevalence and analyzed the associated factors. Results: Recent travel history was associated with IgM levels. Convalescents who had recent travel history were less likely to be IgM antibody negative [OR = 0.232, 95% CI: (0.128, 0.420)]. Asymptomatic cases had, approximately, twice the odds of being IgM antibody negative compared with symptomatic cases [OR = 2.583, 95% CI: (1.554, 4.293)]. Participants without symptoms were less likely to be IgG seronegative than those with symptoms [OR = 0.511, 95% CI: (0.293, 0.891)]. Convalescents aged 40–59 were less likely to be IgG seronegative than those aged below 20 [OR = 0.364, 95% CI: (0.138, 0.959)]. The duration of positive IgM antibodies persisted 365 days while the IgG persisted more than 399 days. Conclusions: Our findings suggested that recent travel history might be associated with the antibody levels of IgM, while age could be associated with the antibody levels of IgG. Infection type could be associated with both antibody levels of IgM and IgG that declined quicker in asymptomatic cases. Frontiers Media S.A. 2021-10-26 /pmc/articles/PMC8577692/ /pubmed/34765580 http://dx.doi.org/10.3389/fpubh.2021.716483 Text en Copyright © 2021 Zhou, Li, Yang, Yuan, Pan, Cheng, Xiao, Su, Zhu, Xu, Tang, Du, Peng, Chen, Huang, Liao, Xian, Wang, Liu, Zhou, Zhang, Liu, Wu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Public Health Zhou, Lijun Li, Cheng Yang, Huiping Yuan, Heng Pan, Ming Cheng, Xiuwei Xiao, Chongkun Su, Xiaoyan Zhu, Yuanfang Xu, Jianan Tang, Jianxiang Du, Xunbo Peng, Huanwen Chen, Xiao Huang, Tao Liao, Hongxiu Xian, Deqiang Wang, HaoZhou Liu, Wenwu Zhou, Ping Zhang, Zhengdong Liu, Juan Wu, Xianping Zhang, Tao SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China |
title | SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China |
title_full | SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China |
title_fullStr | SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China |
title_full_unstemmed | SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China |
title_short | SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China |
title_sort | sars-cov-2 seroprevalence and profiles among convalescents in sichuan province, china |
topic | Public Health |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577692/ https://www.ncbi.nlm.nih.gov/pubmed/34765580 http://dx.doi.org/10.3389/fpubh.2021.716483 |
work_keys_str_mv | AT zhoulijun sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT licheng sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT yanghuiping sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT yuanheng sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT panming sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT chengxiuwei sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT xiaochongkun sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT suxiaoyan sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT zhuyuanfang sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT xujianan sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT tangjianxiang sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT duxunbo sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT penghuanwen sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT chenxiao sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT huangtao sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT liaohongxiu sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT xiandeqiang sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT wanghaozhou sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT liuwenwu sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT zhouping sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT zhangzhengdong sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT liujuan sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT wuxianping sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina AT zhangtao sarscov2seroprevalenceandprofilesamongconvalescentsinsichuanprovincechina |